Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination…
Firms are optimistic about EXIM freight compared to domestic freight transported through railways- Dun & Bradstreet IRFA Report
MUMBAI, India, Nov. 26, 2024 /PRNewswire/ -- Dun & Bradstreet, a global leader…
Firms are optimistic about EXIM freight compared to domestic freight transported through railways- Dun & Bradstreet IRFA Report
MUMBAI, India, Nov. 26, 2024 /PRNewswire/ -- Dun & Bradstreet, a global leader…
Firms are optimistic about EXIM freight compared to domestic freight transported through railways- Dun & Bradstreet IRFA Report
MUMBAI, India, Nov. 26, 2024 /PRNewswire/ -- Dun & Bradstreet, a global leader…
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at…
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at…
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
November 11, 2024 01:00 ET | Source: Addex Therapeutics Nine-month Results Remain…